Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept for Diabetic Macular Edema
NCT04955171Phase 3Unknown
- Sponsor
- Benha University
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised trial of brolucizumab in diabetic macular edema (DME) (2 arms), sponsored by Benha University. Primary endpoint: Best Corrected Visual Acuity at 12 months. Status: unknown.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT04955171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04955171.